Time to CNS disease in patients with DLBCL and craniofacial involvement. There was a statistically nonsignificant trend toward increased CNS disease in the group with craniofacial involvement (n = 288) vs the group without craniofacial involvement (n = 3838) in the entire population (A; P = .122). There was a significant difference between 205 patients with and 2586 patients without craniofacial involvement in the patients treated without rituximab (B; P = .038). This difference disappeared and the 83 patients with craniofacial involvement developed less CNS disease than 1252 patients without when rituximab was given (C; P = .682). Gray dashed curves represent patients with and black curves represent patients without extralymphatic craniofacial involvement.